C. Seidel

发表

Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.

A. Waage, A. Sundan, S. Lenhoff, 2004, Haematologica.

High levels of soluble syndecan-1 in myeloma-derived bone marrow : modulation of hepatocyte growth factor activity

Dianjun Cao, R. Sanderson, A. Waage, 2000 .

Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.

A. Waage, A. Sundan, H. Hjorth-Hansen, 2001, Blood.

The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies.

A. Sundan, H. Hjorth-Hansen, C. Seidel, 1999, Leukemia & lymphoma.

Role of hepatocyte growth factor and its receptorc-met in multiple myeloma

A. Waage, A. Sundan, H. Hjorth-Hansen, 1998, Medical oncology.

Hepatocyte growth factor and its receptor c-met in multiple myeloma.

A. Waage, A. Sundan, H. Hjorth-Hansen, 1996, Blood.

Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease

A. Waage, A. Sundan, M. Torgersen, 1999 .

Serglycin Constitutively Secreted by Myeloma Plasma Cells Is a Potent Inhibitor of Bone Mineralization in Vitro*

A. Theocharis, N. Karamanos, A. Hjerpe, 2006, Journal of Biological Chemistry.

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease.

A. Waage, A. Sundan, N. Abildgaard, 2001, Blood.

Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor.

A. Waage, A. Sundan, S. Lenhoff, 2002, Blood.

A sandwich ELISA for the estimation of human syndecan-2 and syndecan-4 in biological samples.

A. Theocharis, A. Hjerpe, K. Dobra, 2004, Journal of Pharmaceutical and Biomedical Analysis.

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.

T. Plesner, R. Sanderson, A. Waage, 2002, Blood.

Apoptosis, proliferation and NF‐κB activation induced by agonistic Fas antibodies in the human myeloma cell line OH‐2: amplification of Fas‐mediated apoptosis by tumor necrosis factor

A. Waage, T. Espevik, A. Sundan, 1999, European journal of haematology.

with lytic bone disease Serum osteoprotegerin levels are reduced in patients with multiple myeloma

A. Waage, A. Sundan, N. Abildgaard, 2013 .

Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.

A. Sundan, M. Torgersen, H. Hjorth-Hansen, 1999, Blood.

Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia

A. Sundan, J. Lamvik, H. Hjorth-Hansen, 1999, European journal of haematology.

Increased levels of syndecan-1 in serum during acute graft-versus-host disease.

M. Remberger, O. Ringdén, C. Seidel, 2003, Transplantation.

Hepatocyte growth factor in myeloma patients treated with high‐dose chemotherapy

A. Waage, S. Lenhoff, I. Turesson, 2002, British journal of haematology.

Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis.

A. Sundan, A. Faxvaag, M. Ostensen, 2001, Scandinavian journal of rheumatology.

Serum syndecan-1: a new independent prognostic marker in multiple myeloma.

A. Waage, A. Sundan, N. Abildgaard, 2000, Blood.

Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.

A. Waage, A. Sundan, N. Abildgaard, 1998, Blood.

Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells

J. Woodliff, J. Epstein, A. Waage, 2000, British journal of haematology.

Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals

J. Hansen, B. Bendz, P. Sandset, 1999, British journal of haematology.

Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count.

P. Bierling, A. Waage, A. Sundan, 2005, Haematologica.

Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors

E. Holmberg, A. Waage, A. Odén, 1999, British journal of haematology.

Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.

O. Haas, M. Schrappe, A. Waage, 1995 .

High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity.

Dianjun Cao, R. Sanderson, A. Waage, 2000, Blood.

Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients

J. Jelinek, H. Kantarjian, Y. Kanda, 1994 .

Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.

A. Waage, A. Sundan, S. Lenhoff, 1997 .

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.

T. Plesner, R. Sanderson, A. Waage, 2002, Blood.

Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.

A. Sundan, S. Lenhoff, G. Calori, 1995 .

Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine

A. Sundan, P. Musto, S. Lenhoff, 1995 .

Hepatocyte growth factor and its receptor c-met in multiple myeloma.

A. Waage, A. Sundan, H. Hjorth-Hansen, 1996, Blood.